Kenneth Valenzano

Kenneth Valenzano has extensive work experience in the pharmaceutical industry. Kenneth is currently serving as a Scientific Consultant at Congruence Therapeutics since October 2022. Prior to this, they held the role of Chief Scientific Officer at the same company from January 2022 until October 2022.

Before joining Congruence Therapeutics, Kenneth worked at Amicus Therapeutics for a significant period of time. Kenneth'sroles at Amicus Therapeutics included Senior Scientific Advisor since May 2018 and Sr. Vice President of Preclinical Research from November 2013 to May 2018. Kenneth also held the positions of Vice President of Preclinical Research from May 2010 to November 2013, Sr. Director of Pharmacology from April 2007 to May 2010, and Director of Pharmacology from July 2005 to April 2007.

Prior to their tenure at Amicus Therapeutics, Kenneth Valenzano served as a Group Leader of Molecular Pharmacology at Purdue Pharma from July 1999 to June 2005. Kenneth also worked as a Research Scientist at Pharmacopeia from September 1998 to June 1999.

Overall, Kenneth Valenzano has held various scientific and leadership roles throughout their career, contributing to the advancement of pharmaceutical research and development.

Kenneth Valenzano began their education at Bishop Eustace Prep School from 1982 to 1986. Kenneth then attended Villanova University from 1986 to 1990, where they obtained a Bachelor of Arts degree in Biology. Following this, they enrolled at Rutgers University from 1990 to 1995, working towards a Ph.D. in Pharmacology in the laboratory of Dr. Peter Lobel. After completing their Ph.D., Kenneth pursued a post-doctoral fellowship at Duke University from 1995 to 1998, specializing in the Laboratory of Dr. Marc Caron.